Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy New Year to all!
May the new year bring all that is good - into your life.
Bruce, just found an interesting site.
Thought you (and other technically minded persons) may have fun flipping through the reviews etc:
http://www.autohotkey.com/forum/index.php
Have a Safe and Happy Holiday season and all the Best of Wishes for your New Year!
Thanks. You just confirmed my suspicions. I do like the look of it. I browsed around the Vista previews as well. Looks good.
Are you using it? I have the invite but hesitate to use it, because I have to send a lot of documents to other users who will not have it. I doubt if they would be able to use them without converting them back to XP or 2003.
Must be cool there, for you to want to heat it up???
Nice pics though! I know practice, practice, and more practice.
Thats a hard job.
Gonna be one happy fella! Way to go Bruce.
Yeah, guess your right! My Jimmy can take the drifts -LOL. What fun it is. Nite guys, early start tomorrow, have to shovel before I go to work.
You are lucky: Temp -10*F/Windchill -40*F/Gusty to 35 mph.
You really are lucky. Come to the dry ole prairies. :)
Just thinking about Vista. Found some interesting info:
http://news.com.com/The+dawn+of+Vista/2009-1016_3-6132982.html?tag=cnetfd.mt
Looks interesting.
Thats it - Spysweeper gone.
AVG Anti-Spyware and virus protection, now in place.
Since the upgrade, my computer had slowed considerably. It was because of Spysweeper.
Thanks for the help in making my decision.
From the sights and sounds, you are building something. Question is WHAT???? Another terminator?? or two??
At lease they have a 4 year breathing space for the existing trusts, from what I understand (ERF.UN)
Ace Utilities also has an update.
I did and it works great.
FireFox 2.0 is out
http://www.filehippo.com/download_firefox/
Looking good.
Now that's what I call a pro-setup.
Beats me. I am not trading until after the US election. Not a good time for me.
Nice - I want...I want...
Sure wish I could afford :(
That is a great looking setup. Enjoy.
Makes my two screens look small :(
Fantastic machine. Have fun and enjoy. It should be pure delight to use it for your games.
Ouch - That hurts Bruce. Are you able to collect on the $100,000 insurance they provide with UPC machines? That could offset some of the replacement costs. Unfortunately not much can be done about the info unless you had a disconnected external HD. Good luck and have fun replacing everything. Can't wait to see what you decide to build.
OTG
Both were paid up versions. Don't want to part with my Spyware though. Rather use it than AdAware. That's what I have been doing while my AdAware hasn't been working. I got rid of all my Norton except for a line in the startup which I just can't seem to delete. That's the only other problem I have been having. Thanks for the help.
I defraged about two weeks ago. This computer is idle most of the time in the summer as I Daytrade in the fall and winter. My Ad Aware wasn't working before the defrag and that didn't solve the problem. I uninstalled my version, downloaded and installed again (the newer version) and it still hangs. Someone mentioned something called No AdAware. Is that a virus that blocks it? I have run spyweeper and it has not found anything yet. Any ideas?
Any one having trouble with Ad aware freezing? It gets in a few files and then locks my machine up???
Good idea, Thanks
Just the regular doldrums. The charts need a break before the fall run - cheers and Happy Rading..
Still had some problems with the other programs so I uninstalled all of the April updates. So far so good. A lot fewer problems now.
I just uninstalled the KB908531 update and that seems to be helping my mouse problem. Haven't tried the other MS apps yet. Just happy to have my mouse working right again.
VAS-T Sedar - 2 reports plus NR 84m at 2.23
NB: This is just a portion of the release.
Vasogen loss stays flat at $19.3-million in Q1
2006-04-17 17:35 ET - News Release
Mr. Terrance Gregg reports
VASOGEN ANNOUNCES FIRST QUARTER 2006 RESULTS
Vasogen Inc. today released the results of operations for the three months ended Feb. 28, 2006.
At Feb. 28, 2006, the company's cash and cash equivalents, restricted cash and marketable securities held to maturity totalled $61.0-million, compared with $85.2-million at Nov. 30, 2005.
The company incurred a net loss for the three months ended Feb. 28, 2006, of $19.3-million, or 23 cents per common share, compared with a net loss of $19.9-million, or 27 cents per common share for the similar period in 2005. The loss has decreased as a result of a reduction in the costs associated with the company's phase III clinical programs and has been partially offset by expenses associated with the senior convertible notes. The difference between cash used in operations and the company's accounting loss includes such non-cash items as stock option grant expense, amortization expense, accretion and amortization of costs associated with the senior convertible notes payable, offset by payment of accrued expenses related to the company's phase III clinical trials.
For the three months ended Feb. 28, 2006, research and development expenditures decreased to $11.4-million from $16.8-million for the same period in 2005. The majority of the decrease in the company's research and development expense for the three months ended Feb. 28, 2006, when compared with the same period in 2005, resulted from a significant reduction in the clinical trial activities relating to the company's phase III programs.
General and administrative expenditures were $4.9-million for the three months ended Feb. 28, 2006, compared with $5.4-million for the same period in 2005.
Highlights
During the quarter, final patient assessments were completed in the 2,400-patient multinational pivotal phase III Acclaim trial of patients with advanced chronic heart failure. The Acclaim trial is designed to definitively assess the impact of the company's Celacade technology on reducing the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure. Based on the company's current timeline projections for completing the processes necessary to lock the Acclaim database, the company expects to report the initial results from this trial in the first half of 2006.
In March, 2006, the results of the Simpadico trial were presented at a late-breaking clinical trial session of the 55th Annual Scientific Session of the American College of Cardiology in Atlanta. While the Simpadico study did not reach the primary end point of change in maximal treadmill walking distance, therapy using the company's Celacade technology significantly reduced high-sensitivity C-reactive protein, a prespecified end point and a widely recognized marker of systemic inflammation associated with increased cardiovascular risk, including heart failure, stroke and heart attack. Therapy using the company's Celacade technology was also shown to significantly reduce the number of patients progressing to critical limb ischemia, a condition manifested by sharply diminished blood flow to the legs often resulting in the need for amputation. Exploratory analyses of the per-protocol population also showed improvements in certain quality-of-life measures and a statistically significant improvement in ankle-brachial index (measure of change in blood flow to the legs) at 26 weeks in the Celacade group.
On March 22, 2006, following the company's annual meeting of shareholders, Terrance H. Gregg succeeded William R. Grant as chairman of the company's board of directors. Mr. Gregg, who joined Vasogen's board of directors in 1999, has been vice-chairman since November, 2005, and has served as the chair of the compensation, nominating and corporate governance committee of the board for the past several years. Mr. Gregg's extensive experience in the health care sector includes his role as president and chief operating officer of MiniMed Inc., where he successfully transformed the company from a development-stage therapeutic device-company into a global leader in diabetes management systems. In 2001, Medtronic acquired MiniMed for $3.4-billion (U.S.). William R. Grant, who has served as Vasogen's chairman for the last five years, will remain a director on Vasogen's board.
The company also announced the appointment of Ronald M. Cresswell, PhD, hon. DSc, FRSE, former senior vice-president and chief scientific officer of Warner-Lambert, and Calvin R. Stiller, CM, O.ONT, MD, FRCP (C), co-founder and former chairman/chief executive officer of the Canadian Medical Discoveries Fund, to the company's board of directors during the quarter. Both Dr. Cresswell and Dr. Stiller have considerable experience directing the research, development and business initiatives of companies commercializing products for the health care industry. Dr. Cresswell has over 30 years of research and commercial development experience in cardiovascular and other important therapeutic areas and his vision and leadership in the development of Lipitor was instrumental in the product's ultimate success. Dr. Stiller was principal investigator of the Canadian multicentre study that established the importance of cyclosporine and led to its worldwide use as first-line therapy for transplant rejection.
As previously announced, a conference call and slide presentation will be conducted on April 18, 2006, at 8:30 a.m. Eastern Time. The slide presentation may be viewed at Vasogen's website, and the conference call may be accessed by calling 416-695-6622 or 1-800-769-8320, 10 minutes prior to the call. An audio webcast of the event will also be available at Vasogen's website. A rebroadcast of the conference call may be accessed by calling 1-800-293-5765, pin code 8019, and will also be available at Vasogen's website.
Happy Easter all. Problems solved. They just updated the widget engine 3.1.1 and now my widgets work fine.
Apparently there were quite a few that took exection to the upgrade. For me, they have fixed the big. The widgets are just great as far as I am concerned. With this being a year of unstable weather, I like having the latest weather at my fingertips..
Bruce, the "Forecaster" is one of the widgets that doesn't work for me. Here is the link to the forum: http://www2.konfabulator.com/forums/index.php?showtopic=14101
I turned off all the spyware stuff - Redownloaded and it still won't work. Thanks.
Just downloaded it again and it comes up with the error message that the main xml file is missing or unreadable.???
My other widgets work fine
Maybe they have changed the program. I'll try to download it again. It wouldn't even start before. Thanks. I'll get back to you soon.
Yes, I found the problem - now to fix it. The widget is on the yahoo download site. Apparently to fix it you must remove the © symbol from the xml file.????? How do I do that?
The answer was in the workshop forum.
Anyone here have a copy of the old "Forecaster widget" (2.1 v) The new one doesn't work (missing XML file)and yahoo's doesn't work for Canada. I managed to overwrite my old one when I downloaded the upgrade and I can't seem to get it back. Thanks.
MPH-T NR 80m at 2.00
Globe/DJ say Medicure beats hopeful on phase III study
2006-04-13 06:55 ET - In the News
The Globe and Mail reports in its Thursday, April 13, edition that Medicure is moving forward with a single confirmatory phase III study to gain approval for its MC-1 product to reduce cardiovascular events in patients undergoing coronary artery bypass graft surgery. A Dow Jones dispatch to The Globe reports the company said MC-1 has received a fast-track designation from the United Sates Food and Drug Administration. Introduction of the latest study is targeted for the second half of 2006. Medicure stock climbed 22 cents to close at $2. Medicure trades on the Toronto Stock Exchange. The stock has a 52-week trading range of $2.37 to 72 cents. National Bank Financial analyst Andre Uddin rated the stock "outperform" in The Globe on Sept. 15. He gave the stock a 12-month target price of $3.25. The stock has since climbed 82 cents. At the time Medicure president Albert Friesen said there was "extensive interest" by potential drug company partners. The Globe reported on Dec. 12 that analysts were predicting the biotech industry was turning the corner. Medicure stock has since advanced 47 cents. A $1,000 investment on Dec. 12 would now be worth $1,886.79.
DDS-T NR today 43m at 8.98
Globe says Labopharm's tramadol looking good
2006-04-13 06:28 ET - In the News
The Globe and Mail reports in its Thursday edition that Labopharm said Wednesday its once-daily formulation of the tramadol painkiller did well in a phase III clinical trial. The Globe's Leonard Zehr writes the stage is set for regulatory approval of the drug in the U.S. on Sept. 28. Labopharm stock jumped 56 cents to close Wednesday in Toronto at $8.98. The stock hit an intraday high of $9.30. "We are extremely pleased with these results," said chief executive officer James Howard-Tripp. "This data enhances our NDA." The latest results will help bolster Labopharm's new drug application for the drug in the United States. The study compared the safety and effectiveness of the drug versus placebo over a 12-week period in patients diagnosed with moderate to severe pain from osteoarthritis of the knee. Merrill Lynch predicts Labopharm will turn the corner and become profitable for the first time in 2007, thanks to tramadol driving revenue to $90-million from $30-million this year. Labopharm has regulatory approval to sell its once-daily tramadol in the European Union. Labopharm's medication was also accepted for review by the U.S. Food and Drug Administration last November.
QLT-T NR today 91m at 8.64
Globe says QLT cuts out annual report to save money
2006-04-12 08:41 ET - In the News
The Globe and Mail reports in its Wednesday edition in a move to reduce costs, QLT is not producing an annual report for 2005. The Globe's Leonard Zehr writes the move comes in a letter to shareholders from president and chief executive officer Robert Butchofsky. Instead, the drug developer will limit its annual reporting to a 10-K filing with securities regulators. The cost of design, print and mail for the annual report averages about $250,000. In the information circular for the annual meeting on May 9, the company said Mr. Butchofsky is paid a base salary of $520,000 (U.S.) a year. As of last September, when he was appointed interim CEO, replacing Paul Hastings. Mr. Hastings's salary in 2005 was $517,407 (U.S.). He did not receive a bonus but his severance payments will total about $2.9-million. QLT shares rose two cents Tuesday to $8.64 on the Toronto Stock Exchange
MPH-T NR today 79m at 1.78
Medicure plans MC-1 phase III study
2006-04-12 08:26 ET - News Release
Mr. Derek Reimer reports
MEDICURE REPORTS ON MEND-CABG END OF PHASE II MEETING WITH THE FDA
Based on the positive phase II MEND-CABG study and a recent end of phase II meeting with the U.S. Food and Drug Administration, Medicure Inc. plans to proceed with a single confirmatory phase III study to gain approval for MC-1 in the reduction of cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery. MC-1 has received a fast-track designation from the FDA.
Based on the end of phase II meeting, Medicure plans to use a composite of cardiovascular death and non-fatal myocardial infarction (primary definition peak CK-MB greater than or equal to 100 nanograms per millilitre) at postoperative day 30 as the primary end point for the phase III study. Initiation of this study is targeted for the second half of calendar 2006.
"We are extremely pleased with the outcome of the end of phase II meeting with the FDA. A single confirmatory study provides Medicure the most efficient and affordable path for MC-1's phase III development, and is a valuable asset in our partnership negotiations," commented Medicure's president and chief executive officer, Albert D. Friesen, PhD. "MC-1 has the opportunity to be the first product indicated to reduce cardiovascular events associated with ischemia and/or ischemic reperfusion injury in CABG patients, targeting a significant unmet medical need. We look forward to working with the FDA in expediting the development of MC-1."
MC-1 is a small molecule that reduces the amount of damage to the heart following ischemia and/or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function. MC-1's cardioprotective properties have been demonstrated in the phase II MEND-1 study in patients undergoing percutaneous coronary interventions and the phase II MEND-CABG study in patients undergoing CABG surgery.
We seek Safe Harbor.
DDS-T NR today 43m at 8.42
Labopharm gets significant statistics in tramadol trial
2006-04-12 07:17 ET - News Release
Mr. James Howard-Tripp reports
LABOPHARM REPORTS POSITIVE RESULTS FOR PHASE III STUDY ON ONCE-DAILY TRAMADOL - RESULTS TO BE ADDED TO NDA WITH PDUFA DATE OF SEPTEMBER 28, 2006
Labopharm Inc.'s recently completed multicentre phase III clinical trial (MDT3-005) for its once-daily formulation of tramadol achieved statistical significance for the primary end point.
"We are extremely pleased with these results. This data enhances our NDA currently being reviewed by the Food and Drug Administration," said James R. Howard-Tripp, president and chief executive officer, Labopharm.
The results of the study will be added to the company's new drug application (NDA) for once-daily tramadol in the United States, which is currently under review by the Food and Drug Administration (FDA). Based on discussions with the FDA, the company plans to submit the data on a timely basis such that the action date under the Prescription Drug User Fee Act (PDUFA) remains Sept. 28, 2006.
Results of the study
The randomized, double-blind, multicentre parallel study conducted under a special protocol assessment with the FDA, compared the safety and efficacy of Labopharm's once-daily formulation of tramadol to placebo over a 12-week period. Enrolment in the trial consisted of patients diagnosed with moderate to severe pain associated with osteoarthritis of the knee. Patients were randomized to treatment with Labopharm's once-daily tramadol or placebo and underwent double-blind titration to an optimal dose of either 200 or 300 milligrams. The optimal dose for each patient, which was maintained for a period of 12 weeks, was selected based on the effectiveness of pain relief and the tolerability of adverse events. Approximately 1,000 patients were enrolled in this trial.
The primary end point of the study was to compare baseline pain intensity with pain intensity at the end of the study period as measured by the 11-point pain intensity numerical rating score (PI-NRS) in the once-daily tramadol group versus the placebo group. Statistical significance was achieved for the primary end point (p value of 0.0157) and was maintained under additional methods of analysis. The dropout rate was comparable with that of the company's European phase III trial (MDT3-001). The incidence of adverse events was lower than in study MDT3-001, and similar to the previous two United States phase III clinical trials (MDT3-002 and MDT3-003).
We seek Safe Harbor.
CVQ-T NR today 102m at 3.00
Van Sun says CV Technologies gets case of reticence
2006-04-12 09:28 ET - In the News
The Vancouver Sun reports in its Wednesday edition in February, The Sun questioned studies that support the medical value of CV Technologies' COLD-fX product. The Sun's David Baines writes that chief executive officer Jacqueline Shan then launched a counteroffensive. Mr. Shan announced "another clinical study of COLD-fX has met rigorous scientific scrutiny and has been accepted by a peer-reviewed journal for publication." The study is published in the Journal of Alternative and Complementary Medicine. "It is apparent from this study that COLD-fX treatment was effective in reducing the incidence and duration of ARI- [acute respiratory illness] related symptoms in healthy community-dwelling adults aged 65 years and older," it said. Curiously, given such a strong endorsement and the company's practice of using trial results to promote its product, CV Technologies has not reported any of the results in its news releases or advertisements. Mr. Baines also asked several questions about the researchers' methodology and what the researchers specifically intended to measure. He also asked why the study, which was conducted in 1998, is just now being published. In all cases, company officials did not respond.